Tencent (SEHK:00700) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Company ParticipantsAlex Liu - VPEllie Jiang - Head of Asia Internet and SoftwareJames Mitchell - Chief Strategy Officer and Senior Executive Vice PresidentJohn Choi - Executive DirectorJohn Lo - CFO and SVPKenneth Fong - Executive Director and Investment ConsultantMartin Lau - PresidentPony Ma - Co -Founder, Chairman, and CEORonald Keung - Managing DirectorWendy Huang - Director of Investor RelationsConference Call ParticipantsAlex Yao - ...

Yuanbao (NasdaqGM:YB) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Speaker3Ladies and gentlemen, good day, and welcome to Yuanbao Inc.'s fourth quarter and fiscal year 2025 earnings conference call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Ms. Stella Liu, Investor Relations and Strategy Associate Director. Please go ahead.Speaker5Thank you, operator. Please note that today's discussion will contain forward-looking statements made under the safe harbor p ...

Macy’s (NYSE:M) Q4 2026 Earnings call March 18, 2026 08:00 AM ET Speaker8Greetings, and welcome to the Macy's, Inc. fourth quarter 2025 earnings conference call. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this call is being recorded. I would now like to turn the call over to Pam Quintiliano, Vice ...

Kanzhun (NasdaqGS:BZ) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Speaker3Ladies and gentlemen, thank you for standing by, and welcome to Kanzhun Limited fourth quarter and fiscal year 2025 financial results conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a Q&A session. Today's conference is being recorded. At this time, I'd like to turn the conference over to Ms. Laura Chan, Senior Manager of Investor Relations. Please go ahead ...

Tencent (SEHK:00700) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Speaker13Good day and good evening. Thank you for standing by. Welcome to Tencent Holdings Limited 2025 fourth quarter results announcement webinar. I'm Wendy Huang from Tencent IR team. At this time, all participants are in a listen-only mode. After the management's presentation, there will be a question and answer session. For participants who dial in by phone, if you wish to ask a question, please press 5 on your telephone to raise you ...

XOMA Corporation (NasdaqGM:XOMA) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Speaker5Good day, everyone. My name is Kahealani, and I'll be your conference operator today. At this time, I would like to welcome you to the XOMA Royalty 2025 financial results and business highlights investor call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, and if you have join ...

Hello Group (NasdaqGS:MOMO) Q4 2025 Earnings call March 18, 2026 08:00 AM ET Speaker3Ladies and gentlemen, thank you for standing by and welcome to Hello Group's fourth quarter 2025 earnings conference call. All participants are in listen-only mode. There will be a presentation followed by a question-and-answer session. If you wish to ask a question, you will need to press the star key followed by the number one on your telephone keypad. Please note this conference is being recorded today. I would now like ...

Fiscal 2026 Q3 Earnings March 18, 2026 A Reminder on Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management's current expectations and assumptions. These forward-looking statements including the statements under the caption "Reaffirming Fiscal 2026 Financial Outlook," and statements made by Mr. Harmening and Mr. Bruce, are subject to certain risks and uncertainties that could cau ...

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - Cash equivalents and short-term bank deposits as of December 31, 2025, were $30.3 million, with a projected cash balance of approximately $50 million by early April 2026 due to a $25 million milestone payment [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The company anticipates that the approval of the every four weeks regimen in Europe will significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, including PRX-115 for uncontrolled gout and PRX-119 for renal conditions, with expectations of significant market opportunities [5][6] - The company aims to solidify its revenue mix towards Chiesi, which represents the majority of long-term revenue opportunities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong business flexibility and a growing commercial foundation through partners [12] - The projected revenue growth in 2026 of greater than 50% is attributed to the increasing number of patients on Elfabrio [12] Other Important Information - The company is expanding its renal pipeline through collaborations and expects to provide updates on specific indications by the end of Q2 [24] - The approval of the every four weeks regimen in Europe is expected to enhance the competitive edge of Elfabrio [17] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. - Management noted that Chiesi is implementing various promotional activities, including patient ambassador programs, to increase market uptake [16] Question: Positioning of PRX-115 in the gout market - Management highlighted that PRX-115 could offer significant differentiation in dosing frequency and potential safety advantages, targeting a market expected to exceed $2 billion [20] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management indicated that availability will vary by country, with expectations for some markets to see rollout in the second half of 2026 [30]

Financial Data and Key Metrics Changes - In 2025, the group revenue grew 5.9% year-over-year to CNY 25.3 billion, with Legacy-Huazhu's revenue rising by 7.9% to CNY 20.5 billion [23][24] - Group adjusted EBITDA increased 24.2% year-over-year to CNY 8.5 billion, with a margin improvement of 4.9 percentage points to 33.5% [23][24] - Adjusted net income rose by 32.9% year-over-year to CNY 4.9 billion [24] Business Line Data and Key Metrics Changes - The managed and franchised revenue increased by 23.1% year-over-year to CNY 11.7 billion, with gross operating profit rising by 20.8% to CNY 7.6 billion [24] - The number of rooms in operation grew by 16.2% year-over-year, contributing to a group hotel GMV increase of 16.4% to CNY 108.1 billion [9][24] - Room nights sold to members rose 21.5% year-over-year, exceeding 245 million in 2025 [9] Market Data and Key Metrics Changes - Demand for travel in China is shifting from discretionary to necessity, with increasing trips and consumer spending [4] - The hotel industry faces oversupply of low-quality products, while high-quality supply remains insufficient, indicating a need for supply-side reform [5] Company Strategy and Development Direction - The company focuses on economy and mid-scale segments, aiming to provide value-for-money products and expand into lower-tier cities [5][6] - A brand-led approach is emphasized for high-quality growth, with ongoing upgrades to products and services [8][16] - The company aims to achieve a strategic goal of 2,000 cities and 20,000 hotels by 2030 [16] Management's Comments on Operating Environment and Future Outlook - Management is cautiously optimistic about RevPAR performance in 2026, expecting a flat to slight year-over-year increase [38] - The company plans to continue enhancing customer experience and operational efficiency while leveraging technology [16][21] Other Important Information - The company declared a $400 million cash dividend for the second half of 2025, contributing to a total shareholder return of approximately $760 million for the year [25] - A new CFO, Arthur Yu, has been appointed, with a focus on building a world-class finance function and maintaining transparent communications [29] Q&A Session Summary Question: Direction of the new CFO's role and expected changes - Management expressed confidence in the new CFO's ability to lead the company towards becoming a global leader, emphasizing the need for world-class management talent [31][34] Question: 2026 revenue guidance and demand-supply outlook - Management noted a recovering hotel industry in China, with growing leisure travel demand and a cautious optimism for RevPAR performance in 2026 [36][38] Question: Hotel opening pace and new brand targets - The company plans to open 2,200-2,300 new hotels in 2026, focusing on high-quality growth rather than just quantity [40][41] Question: Asset-light transformation strategy for Legacy-DH - Management highlighted ongoing efforts in cost control and portfolio restructuring, with plans to expand the hotel network internationally [47][48] Question: Future shareholder return plans - The company is committed to returning value to shareholders through dividends and share repurchases, supported by strong cash flow [50][52] Question: Plans for the upper mid-scale hotel segment - The company aims to become a leading brand in the upper mid-scale sector by 2030, focusing on a multi-brand strategy [54][56]